Analysts Offer Predictions for ACRS FY2025 Earnings

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) – Equities research analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Aclaris Therapeutics in a report released on Tuesday, March 4th. Cantor Fitzgerald analyst P. Agrawal forecasts that the biotechnology company will post earnings of ($0.54) per share for the year. Cantor Fitzgerald currently has a “Strong-Buy” rating on the stock. The consensus estimate for Aclaris Therapeutics’ current full-year earnings is ($0.82) per share.

Several other research analysts have also recently issued reports on the company. StockNews.com cut Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 8th. Jefferies Financial Group upgraded Aclaris Therapeutics from a “hold” rating to a “buy” rating and boosted their price target for the company from $2.00 to $7.00 in a research report on Tuesday, November 19th. HC Wainwright raised shares of Aclaris Therapeutics from a “neutral” rating to a “buy” rating and set a $20.00 target price on the stock in a report on Monday, December 23rd. Leerink Partnrs raised Aclaris Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, November 19th. Finally, BTIG Research raised shares of Aclaris Therapeutics from a “neutral” rating to a “buy” rating and set a $8.00 price target on the stock in a research note on Tuesday, November 19th. One equities research analyst has rated the stock with a sell rating, five have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, Aclaris Therapeutics currently has an average rating of “Buy” and an average price target of $11.00.

Aclaris Therapeutics Trading Down 1.6 %

NASDAQ:ACRS opened at $1.82 on Thursday. The stock has a fifty day moving average price of $2.36 and a 200 day moving average price of $2.17. The firm has a market cap of $130.00 million, a PE ratio of -3.50 and a beta of 0.50. Aclaris Therapeutics has a 12-month low of $0.95 and a 12-month high of $5.17.

Institutional Trading of Aclaris Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in ACRS. BML Capital Management LLC increased its position in Aclaris Therapeutics by 9.7% during the 3rd quarter. BML Capital Management LLC now owns 14,250,000 shares of the biotechnology company’s stock worth $16,388,000 after purchasing an additional 1,261,866 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Aclaris Therapeutics by 187.6% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 332,406 shares of the biotechnology company’s stock worth $382,000 after purchasing an additional 216,826 shares during the last quarter. Stonepine Capital Management LLC grew its holdings in shares of Aclaris Therapeutics by 27.6% during the third quarter. Stonepine Capital Management LLC now owns 2,458,873 shares of the biotechnology company’s stock worth $2,828,000 after buying an additional 531,427 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Aclaris Therapeutics during the third quarter worth about $1,053,000. Finally, Geode Capital Management LLC raised its position in shares of Aclaris Therapeutics by 9.3% in the third quarter. Geode Capital Management LLC now owns 846,446 shares of the biotechnology company’s stock valued at $974,000 after buying an additional 72,309 shares during the last quarter. 98.34% of the stock is currently owned by hedge funds and other institutional investors.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.